

December 18, 2025  
Meeting was convened at 11:00 AM  
Hybrid Meeting

Voting Members Present:

- |   |   |   |
|---|---|---|
| <input checked="" type="checkbox"/> Cecilia Gerstner (IBC Chair)    | <input checked="" type="checkbox"/> Scott Cho (IBC Member)        | <input type="checkbox"/> Alton Swennes (Animal Expert)          |
| <input checked="" type="checkbox"/> Jeff Clifford (IBC Vice Chair)  | <input checked="" type="checkbox"/> David Gillespie (IBC Member)  | <input checked="" type="checkbox"/> David Thomas (IBC Member)   |
| <input checked="" type="checkbox"/> Debbie Eckert (BSO)             | <input type="checkbox"/> Talia Karasov (Plant Expert)             | <input checked="" type="checkbox"/> Michael Voight (IBC Member) |
| <input checked="" type="checkbox"/> Chris Hunter (ABSO)             | <input type="checkbox"/> John Kriesel (HGT Expert)                | <input type="checkbox"/> Tom Wachter (IBC Member)               |
| <input checked="" type="checkbox"/> Isaac Martineau (BS Specialist) | <input checked="" type="checkbox"/> Karla McHale (IBC Member)     | <input type="checkbox"/> Zemin Zhou (IBC Member)                |
| <input checked="" type="checkbox"/> Ricky Bell (IBC Member)         | <input type="checkbox"/> Bart Mickelsen (IBC Member)              | <input checked="" type="checkbox"/> Wendy Zhu (IBC Member)      |
| <input checked="" type="checkbox"/> Neil Bowles (IBC Member)        | <input checked="" type="checkbox"/> Kate Modzelewska (IBC Member) |   |
| <input checked="" type="checkbox"/> Jessica Brown (IBC Member)      | <input checked="" type="checkbox"/> Andy Phillips (IBC Member)    |   |
| <input checked="" type="checkbox"/> Allison Carey (IBC Member)      | <input checked="" type="checkbox"/> Robert Sperling (IBC Member)  |   |

**Visitor:** Erna Serezlic, MBA-HCM  
Clinical Research Manager  
Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI)

Quorum was present; 7 are required to conduct business.

**Conflict of Interest Declaration**

None

**Review of November 20, 2025 Minutes**

Motion: **Approve**  
Vote for Motion: 12 in favor of the motion  
4 Abstain

**Old Business**

**#79-25 Gianna Hammer. Antigen Presenting Cells and Inflammation.**

PI has not responded to post-review memo. Reminder email sent 9/10/25, 10/15/25.  
IBC Chair sent reminder on 12/1/25.

**#96-25 Colin Dale. Characterization of interactions between *Sodalis praecaptivus* and grain weevils. *Sodalis praecaptivus*, transgenic weevils. BSL1/ABSL1. Renewal.**

Studying interactions between bacterial endosymbionts and their insect hosts - currently focusing on grain weevils of the genus *Sitophilus*.

PI responded to post-review memo. Responses were evaluated by BSO and ABSO. Approval granted 11/26/25.

**#124-25 Corrine Welt. The Genetics of Female Reproduction.**

They study the genetics of female reproductive disorders.

Outstanding issues to resolve, which were communicated to PI through post-review memo.

- **SciShield:**
  - In the Project Form *'The Genetics of Female Reproduction'* provide the current IACUC Protocol number. The OACC has identified protocol number 1681 as relevant to this project.
- **In Exposure Control Plan:**
  - Hepatitis B Vaccination Attestation forms are digitally managed by the Occupational Medicine Program.
    - Section 5. Hepatitis B Vaccination: Remove the last three paragraphs of the section starting with "However" and ending with "administered." The Hepatitis B Vaccination program is now managed through Open Range.
    - Remove Appendix D.
- **Documentation:**
  - Provide a statement to clarify if transgenic animals are being created and/or if recombinant DNA is delivered to animal models with this registration.
  - To comply with NIH regulations, the IBC is required to publish minutes from convened meetings, which they provide on the IBC website <https://ibc.utah.edu/meeting-minutes.php> . PI needs to inform us if their IBC registration contains proprietary information that cannot be included in the minutes.
  - The OSHA Bloodborne Pathogen Standards requires enrollment in the Hepatitis B program when working with human source materials, regardless of vaccination status. Contact Dr. Andy Phillips at Occupational Medicine for access to the health screening questionnaire in Open Range. In the email, provide the lab name and all lab personnel uNIDs to Dr. Phillips. Once contact with Dr. Phillips has been obtained this item is considered complete by the IBC.

PI responded to post-review memo. Responses were evaluated by BSO and ABSO. Approval granted 12/9/25.

### **Protocols for Review With 3 Year Approval**

**#127-25 Tracey Lamb. The generation of immune responses to malaria parasites; Suppression of anti-malarial humoral immune responses by gamaherpesviruses; Development of Saccharomyces boulardii as a simultaneous vaccine expression and delivery system; Defining the Mechanisms by which Plasmodium-infection Predisposes Mice to respiratory pathogens.**

All pre-screen comments were resolved and no additional concerns were raised during the meeting.

PI Cites NIH Guidelines: III-D-2, III-D-3, III-D-4, III-D-4-a, III-D-4-b, III-D-4-c-(2), III-D-8, III-E, III-E-1, III-E-3

Agent: Gammaherpes (murine herpesvirus)

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Deletions: M2stop

Insertions: YFP and M2-Cherry from jellyfish.

Agent: Streptococcus pneumoniae

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Agent: RSV

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism   
Antibiotic Resistance

Agent: Murine Stem Cell Virus

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Transgenes and Sources: T Cell Receptor from mouse source.

Agent: LCMV (non-neurotropic)

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Agent: Influenza A (mouse-adapted)

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Insertions: myelin peptide fragment that does not change virulence, host range, or growth characteristics.

Agent: Mouse Polyoma Virus

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Insertions: express model antigens from LCMV, OVA, and Plasmodium

Agent: Plasmodium

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Lab Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Insertions: OVA

Agent: Diphtheria Toxin

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Risk Assessment: Sharps  | Vortexing  | Sonicating  | Cell Sorting  | Centrifuging  | Oncogene

Risk Mitigation: Biosafety Cabinet  | Fume Hood  | Sealed Rotor or Safety Buckets  | Anaesthetization  |

Restraints  | Safer Sharps  | Enhanced PPE  | Treatment Available  | Vaccine Available

Disinfectant: Freshly Prepared 1:10 Dilution of Bleach

PPE: Laboratory Coat, Gloves, Safety Glasses

Motion: Approve at Biosafety Level 2 (BSL-2) and Animal Biosafety Level 2 (ABSL-2)

Vote for Motion: 15 For Motion | 1 Abstain

**#128-25 Randy Peterson. Chemical and genetic screening in the zebrafish; CRISPR screening technology development; Generation and characterization of transgenic and mutant zebrafish; Investigating the roles of**

**redox balance in electron transport chain dysfunction; Understanding the mechanisms of finasteride in the inhibition of addictive behaviors in zebrafish.**

All pre-screen comments were resolved and no additional concerns were raised during the meeting.

PI Cites NIH Guidelines: III-D-4, III-D-4-a, III-E

Agent: Lentivirus

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Transgenes and Sources: PCP, dCas9, luciferase, MCP from bacterial sources

Risk Assessment: Sharps  | Vortexing  | Sonicating  | Cell Sorting  | Centrifuging  | Oncogene

Risk Mitigation: Biosafety Cabinet  | Fume Hood  | Sealed Rotor or Safety Buckets  | Anaesthetization  |

Restraints  | Safer Sharps  | Enhanced PPE  | Treatment Available  | Vaccine Available

Disinfectant: Freshly Prepared 1:10 Dilution of Bleach

PPE: Laboratory Coat, Gloves, Safety Glasses

Motion: Approve at Biosafety Level 2 (BSL-2) and Animal Biosafety Level 1 (ABSL-1)

Vote for Motion: 15 For Motion | 1 Abstain

**#129-25 Brian Evavold. Evaluation of Pathogen and Self-Specific T cell Responses.**

All pre-screen comments were resolved and no additional concerns were raised during the meeting.

PI Cites NIH Guidelines: III-D-1, III-D-3, III-D-4-a, III-D-4-b, III-D-4-c-(2), III-D-4, III-D-7, III-E-3

Agent: Influenza A (mouse-adapted)

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Insertions: myelin peptide fragment that does not change virulence, host range, or growth characteristics.

Agent: LCMV (non-neurotropic)

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Agent: Listeria monocytogenes

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Insertions: myelin peptide fragment that does not change virulence, host range, or growth characteristics.

Agent: Plasmodium (mouse specific)

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Insertions: OVA

Agent: Mouse Polyoma Virus

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples   
Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |  
Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |  
Antibiotic Resistance   
Insertions: express model antigens from LCMV, OVA, and Plasmodium

Agent: Murine Stem Cell Virus  
Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples   
Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |  
Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |  
Antibiotic Resistance   
Transgenes and Sources: T Cell Receptor from mouse source.

Agent: Diphtheria and Pertussis Toxin  
Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples   
Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |  
Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |  
Antibiotic Resistance

Risk Assessment: Sharps  | Vortexing  | Sonicating  | Cell Sorting  | Centrifuging  | Oncogene   
Risk Mitigation: Biosafety Cabinet  | Fume Hood  | Sealed Rotor or Safety Buckets  | Anaesthetization  |  
Restraints  | Safer Sharps  | Enhanced PPE  | Treatment Available  | Vaccine Available   
Disinfectant: Freshly Prepared 1:10 Dilution of Bleach  
PPE: Laboratory Coat, Gloves, Safety Glasses  
Motion: Approve at Biosafety Level 2 (BSL-2) and Animal Biosafety Level 2 (ABSL-2)  
Vote for Motion: 15 For Motion | 1 Abstain

### **#131-25 Luis Batista. Molecular characterization of bone marrow failure disorders with the use of embryonic and induced pluripotent stem cells.**

All pre-screen comments were resolved and no additional concerns were raised during the meeting.

PI Cites NIH Guidelines: III-D-1, III-D-3, III-E, III-E-1  
Agent: Sendai Virus  
Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples   
Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |  
Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |  
Antibiotic Resistance   
Transgenes and Sources: klf4, Oct4, Sox2, Myc from human sources.

Agent: Lentivirus  
Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples   
Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |  
Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |  
Antibiotic Resistance   
Transgenes and Sources: TERT, DKC1, TIN2, USB1, PAPD5, PARN, TRF1, TRF2, TGS1, UPF1 from human.

Risk Assessment: Sharps  | Vortexing  | Sonicating  | Cell Sorting  | Centrifuging  | Oncogene   
Risk Mitigation: Biosafety Cabinet  | Fume Hood  | Sealed Rotor or Safety Buckets  | Anaesthetization  |  
Restraints  | Safer Sharps  | Enhanced PPE  | Treatment Available  | Vaccine Available   
Disinfectant: Freshly Prepared 1:10 Dilution of Bleach  
PPE: Laboratory Coat, Gloves, Safety Glasses  
Motion: Approve at Biosafety Level 2 (BSL-2)  
Vote for Motion: 16 For Motion | Abstain

**#132-25 Bruce Edgar. Control of Cell Growth in the Gut; Control of G1/S progression; Infection of human cell lines using lentivirus; Infection of human mouse intestinal organoids using lentivirus.**

All pre-screen comments were resolved and no additional concerns were raised during the meeting.

PI Cites NIH Guidelines: III-D-1, III-D-3, III-4, III-D-4-a, III-E, III-E-1

Agent: Lentivirus

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Transgenes and Sources: sfGFP and mCherry from jellyfish; ecDHFR from E. coli; CCNE2, DNA2, CDC45, RAD51 from human sources

Risk Assessment: Sharps  | Vortexing  | Sonicating  | Cell Sorting  | Centrifuging  | Oncogene

Risk Mitigation: Biosafety Cabinet  | Fume Hood  | Sealed Rotor or Safety Buckets  | Anaesthetization  |

Restraints  | Safer Sharps  | Enhanced PPE  | Treatment Available  | Vaccine Available

Disinfectant: Freshly Prepared 1:10 Dilution of Bleach

PPE: Laboratory Coat, Gloves, Safety Glasses

Motion: Approve at Biosafety Level 2 (BSL-2) and Animal Biosafety Level 1 (ABSL-1)

Vote for Motion: 16 For Motion | Abstain

**Protocols for Review With 5 Year Approval**

**#130-25 Christopher Zimmerman. Neurobiology of body-brain communication.**

All pre-screen comments were resolved and no additional concerns were raised during the meeting.

PI Cites NIH Guidelines: III-D-4-a, III-E-3

Agent: AAV

Tissue Culture  | Animal Work  | Patient Samples  | Human Gene Transfer  | Environment Samples

Agent Characteristics: Attenuated/Vaccine Strain  | Replication Incompetent  | Replication Competent  |

Second Generation  | Third Generation  | Expanded Tropism  | Narrowed Tropism  | Wild Type Tropism  |

Antibiotic Resistance

Transgenes and Sources: Fluorophores and Indicators from jellyfish source, Opsins from algae source, DREADDs from human source, Silencers from multiple sources

Risk Assessment: Sharps  | Vortexing  | Sonicating  | Cell Sorting  | Centrifuging  | Oncogene

Risk Mitigation: Biosafety Cabinet  | Fume Hood  | Sealed Rotor or Safety Buckets  | Anaesthetization  |

Restraints  | Safer Sharps  | Enhanced PPE  | Treatment Available  | Vaccine Available

Disinfectant: Freshly Prepared 1:10 Dilution of Bleach

PPE: Laboratory Coat, Gloves, Safety Glasses

Motion: Approve at Biosafety Level 1 (BSL-1) and Animal Biosafety Level 1 (ABSL-1)

Vote for Motion: 15 For Motion | 1 Abstain

**Protocols for Review, Requiring IBC Approval Before Initiation, Transfer of rsNA into Humans**

**None**

**Pending Protocols**

**#98-25 Xinbo Yang. Electronics Scrap Recycling Advancement Prize (E-SCRAP). Cellulosimicrobium funkei. BSL-2. New Registration.**

PI has not responded to post-review memo. Reminder email sent 10/9/25, 11/12/25, 12/5/25.

**Lab/Protocol Closures**

None

**Spills and Incidents**

None

**Other Business**

IBC Meetings from January to April will be held in HSEB 2958.

Update on NIH Biosafety Modernization Listening Sessions

Next IBC meeting will be held on January 22, 2026.